Duration of Use of Highly Effective Reversible Contraception

NCT02414919 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13880

Last updated 2017-03-16

No results posted yet for this study

Summary

To assess the proportion of women who use HERC for ≥2 years of duration

Conditions

  • Pregnancy

Interventions

DRUG

Mirena (Levonorgestrel IUS, BAY86-5028)

Levonorgestrel-releasing intrauterine device 20 mcg/day

DRUG

ParaGard

Copper T380A

DRUG

Implanon/Nexplanon

Etonorgestrel contraceptive implant

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
15 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2016-03-28
Completion
2016-03-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414919 on ClinicalTrials.gov